A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- GSK Clinical Trials
GlaxoSmithKline
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Arcadia, California, United States
Elias TarakjiRecruiting - Gsk Investigational Site
Covina, California, United States
Masoud AzizadRecruiting - Gsk Investigational Site
Los Angeles, California, United States
Joseph LambRecruiting - Gsk Investigational Site
Santa Maria, California, United States
Keval ShahRecruiting - Gsk Investigational Site
Van Nuys, California, United States
Robert JendersRecruiting - Gsk Investigational Site
Boynton Beach, Florida, United States
Aaron CohenRecruiting - Gsk Investigational Site
Cape Coral, Florida, United States
Paige KreegelRecruiting - Gsk Investigational Site
Hialeah, Florida, United States
Isaac Bassan, MDRecruiting - Gsk Investigational Site
Hialeah, Florida, United States
Jorge DiazRecruiting - Gsk Investigational Site
Inverness, Florida, United States
Paul Hellstern Jr.Recruiting - Gsk Investigational Site
Jacksonville, Florida, United States
Jeffry JacqmeinRecruiting - Gsk Investigational Site
Kissimmee, Florida, United States
Luis AlvaradoRecruiting - Gsk Investigational Site
Lakeland, Florida, United States
James AndersenRecruiting - Gsk Investigational Site
Maitland, Florida, United States
Eva Maria HeurichRecruiting - Gsk Investigational Site
Miami, Florida, United States
Yaneicy Gonzalez RojasRecruiting - Gsk Investigational Site
Miami, Florida, United States
Carlos RamosRecruiting - Gsk Investigational Site
Miami, Florida, United States
JORGE AMAYARecruiting - Gsk Investigational Site
Miami, Florida, United States
Lazaro M GarciaRecruiting - Gsk Investigational Site
Miami, Florida, United States
Franciso BautistaRecruiting - Gsk Investigational Site
Miami Lakes, Florida, United States
Miguel AponteRecruiting - Gsk Investigational Site
Ocala, Florida, United States
Robert BarishRecruiting - Gsk Investigational Site
Palmetto Bay, Florida, United States
Karen Figueredo ReyesRecruiting - Gsk Investigational Site
Topeka, Kansas, United States
Shekhar ChallaRecruiting - Gsk Investigational Site
Springfield, Missouri, United States
Dmitry ShusterRecruiting - Gsk Investigational Site
St Louis, Missouri, United States
Fred WilliamsRecruiting - Gsk Investigational Site
East Syracuse, New York, United States
Barbara ConnorRecruiting - Gsk Investigational Site
New York, New York, United States
Samar HameedRecruiting - Gsk Investigational Site
New York, New York, United States
Eli ShalenbergRecruiting - Gsk Investigational Site
Morehead City, North Carolina, United States
Kathryn LucasRecruiting - Gsk Investigational Site
Akron, Ohio, United States
Ganesh VeerappanRecruiting - Gsk Investigational Site
Springboro, Ohio, United States
Anjali MoreyRecruiting - Gsk Investigational Site
Chattanooga, Tennessee, United States
Chirag PatelRecruiting - Gsk Investigational Site
Austin, Texas, United States
Michael Patrick ZimmermanRecruiting - Gsk Investigational Site
Austin, Texas, United States
Nomita KimRecruiting - Gsk Investigational Site
Bellaire, Texas, United States
Everald ManningRecruiting - Gsk Investigational Site
Brownsville, Texas, United States
Christopher RomeroRecruiting - Gsk Investigational Site
Dallas, Texas, United States
Valentine EbuhRecruiting - Gsk Investigational Site
DeSoto, Texas, United States
Haresh BogharaRecruiting - Gsk Investigational Site
Richmond, Texas, United States
Brian ChouRecruiting - Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Oct 2025
- Primary completion
- 29 Mar 2028
- Completion
- 12 Dec 2031
- Last update posted
- 16 Apr 2026
- Registered enrollment
- 1,200
- Registry id
- NCT07221227
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.